Volume 8, Number 3—March 2002
Research
The Relationship between Antimicrobial Use and Antimicrobial Resistance in Europe
Stef L.A.M. Bronzwaer*
, Otto Cars†, Udo Buchholz*, Sigvard Mölstad‡, Wim Goettsch*, Irene K. Veldhuijzen*, Jacob L. Kool*, Marc J.W. Sprenger*, John E. Degener§, and participants in the European Antimicrobial Resistance Surveillance System
, Otto Cars†, Udo Buchholz*, Sigvard Mölstad‡, Wim Goettsch*, Irene K. Veldhuijzen*, Jacob L. Kool*, Marc J.W. Sprenger*, John E. Degener§, and participants in the European Antimicrobial Resistance Surveillance System
Table
Number of submitting laboratories, number of isolates of Streptococcus pneumoniae, number (#) and percent (%R) of penicillin nonsusceptible S. pneumoniae isolates, logodds of resistance (ln(%R/[1-%R]), and outpatient sales of beta-lactam antibiotics and macrolides
| Country | No. of labora-tories | No. of S. pneumoniae isolates | Penicillin nonsusceptible S. pneumoniae | Outpatient sales of antibiotics in DDDa/1,000 inhabitants/day | |||
|---|---|---|---|---|---|---|---|
| No. | %R (95% CI) | ln (%R/[1-%R]) | Beta-lactam antibiotics | Macrolides | |||
| Austria | - | - | - | - | - | 6 | 3.7 |
| Belgium | 96 | 940 | 131 | 14 (12-16) | -1.82 | 14 | 4.1 |
| Denmark | - | - | - | - | - | 7 | 2 |
| Finland | 11 | 211 | 8 | 4 (2-8) | -3.18 | 8[REMOVED ADVANCE FIELD] | [REMOVED ADVANCE FIELD]1.9 |
| [REMOVED ADVANCE FIELD]France | [REMOVED ADVANCE FIELD]- | [REMOVED ADVANCE FIELD]- | [REMOVED ADVANCE FIELD]- | [REMOVED ADVANCE FIELD]- | [REMOVED ADVANCE FIELD]- | 24[REMOVED ADVANCE FIELD] | [REMOVED ADVANCE FIELD]6.0 |
| Germany | 15 | 222 | 4 | 2 (1-5) | -3.89 | 5 | 2.5 |
| Iceland | 2 | 54 | 1 | 2 (0-11) | -3.89 | Not available | Not available |
| Ireland | 12 | 157 | 30 | 19 (13-26) | -1.45 | 11 | 2.5 |
| Italy | 46 | 194 | 26 | 13 (9-19) | -1.87 | 15 | 5.1 |
| Luxembourg | 1 | 11 | 2 | 18 (3-52) | -1.52 | 14 | 4.7 |
| Netherlands | 20 | 760 | 8 | 1 (0-2) | -4.6 | 4 | 1.2 |
| Portugal | 12 | 134 | 25 | 19 (13-27) | -1.45 | 16 | 3.7 |
| Spain | 76 | 1,240 | 418 | 34 (31-36) | -0.66 | 21 | 5.9 |
| Sweden | 24 | 706 | 21 | 3 (2-5) | -3.48 | 8 | 1 |
| United Kingdom | 22 | 243 | 21 | 9 (6-13) | -2.31 | 9 | 3.2 |
aDDD = defined daily doses; CI = confidence interval.
Page created: July 15, 2010
Page updated: July 15, 2010
Page reviewed: July 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.